Get the Stockscreener App
6.01
1.15%
-0.07
Upstream Bio Inc stock is traded at $6.01, with a volume of 540.42K.
It is down -1.15% in the last 24 hours and down -11.49% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$6.08
Open:
$6
24h Volume:
540.42K
Relative Volume:
0.89
Market Cap:
$329.17M
Revenue:
$3.32M
Net Income/Loss:
$-156.76M
P/E Ratio:
-2.0711
EPS:
-2.9019
Net Cash Flow:
$-140.13M
1W Performance:
-10.16%
1M Performance:
-11.49%
6M Performance:
-22.95%
1Y Performance:
-69.46%
1-Day Range:
$5.965
$6.23
1-Week Range:
$5.77
$6.98
52-Week Range:
$5.77
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
6.01 | 375.18M | 3.32M | -156.76M | -140.13M | -2.9019 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Nov-18-25 | Initiated | Evercore ISI | Outperform |
| Oct-14-25 | Initiated | Truist | Buy |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
View All
Upstream Bio Inc Stock (UPB) Latest News
Why Did UPB Stock Plunge 40% Today? - Stocktwits
Norges Bank Initiates New Position in Upstream Bio Inc (UPB) with 4.2 Million Share Purchase - GuruFocus
Upstream Bio, Inc. (NASDAQ: UPB) Share Price, UPB Stock News, UPB Share Price & Updates - Kalkine
Walleye Capital LLC Invests $3.45 Million in Upstream Bio, Inc. $UPB - MarketBeat
Upstream Bio (NASDAQ:UPB) Lowered to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Upstream Bio (NASDAQ:UPB) Given New $9.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Q3 EPS Estimates for Upstream Bio Decreased by HC Wainwright - MarketBeat
Marie Sanchirico takes charge of Medical Affairs at Upstream Bio, Inc. to drive physician engagement - Traders Union
Truist Financial Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $25 - Moomoo
H.C. Wainwright Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Upstream Bio (UPB) Slides 2.54% as Biotech Caution Persists: Key Levels to WatchInstitutional Buy Signals - Vinanet
A Quick Look at Today's Ratings for UpStream Bio(UPB.US), With a Forecast Between $19 to $36 - Moomoo
Truist Financial Maintains UpStream Bio(UPB.US) With Buy Rating, Cuts Target Price to $25 - Moomoo
Upstream Bio Targets Q1 2027 Start for Phase - Minichart
Upstream Bio (NASDAQ:UPB) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
UPB: Verekitug demonstrated robust efficacy and safety, advancing to Phase 3 for severe asthma and CRSWNP - TradingView
Upstream Bio posts corporate presentation highlighting verekitug Phase 3 plans in severe asthma, CRSwNP - Bitget
Pstream Bio stock rises 2.6% after Q2 results and pipeline update - Traders Union
Form 8K Upstream Bio Inc For: 11 August By Investing.com - Investing.com Canada
Upstream Bio, Inc. 2Q 2026: Revenue $0.8M, EPS $(0.73) — 10-Q Summary - TradingView
Upstream Bio (UPB) deepens R&D spend but ends quarter with $261M cash - Stock Titan
Upstream Bio Q2 net loss narrows slightly on lower R&D costs - TradingView
Upstream Bio reports Q2 2026 net loss $39.7M, cash and short-term investments $261.3M - TradingView
Upstream Bio Posts $39.7 Million Q2 Net Loss as Trials Advance - Quiver Quantitative
Upstream Bio, Inc. sets Phase 3 trial for sever asthma and CRSwNP in Q1 2027 - Traders Union
Upstream Bio (NASDAQ: UPB) reports Q2 2026 loss and advances Phase 3 plans - Stock Titan
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress - Caledonian Record
Upstream Bio (UPB) Rises 0.94% to $7.51 as Biotech Stock Holds Key SupportAdvance Decline Volume - dars.gov.et
Upstream Bio Inc (UPB) Stock News Today - TradingKey
Upstream Bio Inc (UPB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Upstream Bio, Inc. (UPB) Stock Analysis: A Hidden Gem in Biotechnology with a 456% Potential Upside - DirectorsTalk Interviews
Arrowstreet Capital Limited Partnership Buys New Holdings in Upstream Bio, Inc. $UPB - MarketBeat
BlackRock, Inc. Trims Stake in Upstream Bio Inc (UPB) Amid Clini - GuruFocus
Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Upstream Bio (UPB) Gains Ground: Testing Key Resistance Levels After 2.5% AdvanceBox Spread - dars.gov.et
Upstream Bio (UPB) Expected to Release Quarterly Earnings on Wednesday - MarketBeat
Upstream Bio Inc (UPB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Upstream Bio Inc (UPB) Cash Flow - TradingKey
UPB|Upstream Bio Inc|Price:6.780|Chg%:+0.360 - TradingKey
UPB|Upstream Bio Inc|Price:6.400|Chg%:-0.010 - TradingKey
Upstream Bio Inc (UPB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Upstream Bio Inc (UPB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Upstream Bio Inc (UPB) Balance Sheet - TradingKey
Upstream Bio Inc (UPB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
UPB|Upstream Bio Inc|Price:7.450|Chg%:+0.200 - TradingKey
Upstream Bio Inc. (UPB) Holds Steady Near Support as Traders Eye Resistance BreakoutHigh Yield Stocks - dars.gov.et
Upstream Bio Inc (UPB) Income Statement - TradingKey
Upstream Bio, Inc. Revenue Breakdown – NASDAQ:UPB - TradingView
Upstream Bio (UPB) Holds Steady Near Support as Traders Eye Key Resistance LevelsRip Sell Trade - vinanet.vn
Decheng Capital LLC Sells 418,210 Shares of Upstream Bio, Inc. $UPB - MarketBeat
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Upstream Bio Inc Stock (UPB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sutherland Everett Rand | Chief Executive Officer |
Jun 16 '26 |
Sale |
6.10 |
2,095 |
12,780 |
70,812 |
| Houghton Adam | Chief Business Officer |
Jun 16 '26 |
Sale |
6.10 |
700 |
4,270 |
23,601 |
| Deykin Aaron | Chief Medical Officer |
Jun 16 '26 |
Sale |
6.10 |
895 |
5,460 |
33,197 |
| Ambrose Allison | General Counsel |
Jun 16 '26 |
Sale |
6.10 |
477 |
2,910 |
16,048 |
| GRAY MICHAEL | CFO and COO |
Mar 16 '26 |
Sale |
9.29 |
852 |
7,915 |
29,648 |
| Deykin Aaron | Chief Medical Officer |
Mar 16 '26 |
Sale |
9.29 |
894 |
8,305 |
32,687 |
| Sutherland Everett Rand | Chief Executive Officer |
Mar 16 '26 |
Sale |
9.29 |
2,093 |
19,444 |
72,907 |
| Ambrose Allison | General Counsel |
Mar 16 '26 |
Sale |
9.29 |
475 |
4,413 |
16,525 |
| Houghton Adam | Chief Business Officer |
Mar 16 '26 |
Sale |
9.29 |
699 |
6,494 |
24,301 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):